Anebulo Pharmaceuticals, Inc. (ANEB)
$0.32+3.23%Close
SELLCRISIS · day 16
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $13M
- Beta
- -1.83
- P/E (TTM)
- -2.09
- Short % float
- 1.62%
- Days to cover
- 626.3
- SI change
- -0.1%
- 1W
- +0.00%
- 1M
- -3.03%
- vs SPY 1W
- -1.16%
- vs SPY 1M
- -6.02%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 6
- VALUE
- 14
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-38.7%
REV YoY-
ROE-64.5%
EPS YoY-
ROA-66.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-2.09
P/E FWD-
SECTOR PE20.47
INDUSTRY PE13.95
P/B1.66
P/FCF-
EV/EBITDA-0.64
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO16.71
ND/EBITDA-
BETA-1.83
Company news
FAQ
- What is LOPJLB’s current signal on ANEB?
- LOPJLB’s latest quantitative signal on Anebulo Pharmaceuticals, Inc. (ANEB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ANEB in?
- Anebulo Pharmaceuticals, Inc. (ANEB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Anebulo Pharmaceuticals, Inc. (ANEB) do?
- Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The companyâs lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical …